



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMADOC-1700519818-2039232

## European Medicines Agency decision

EMA/PE/0000232765

of 14 April 2025

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sargramostim in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**



# European Medicines Agency decision

EMA/PE/0000232765

of 14 April 2025

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sargramostim in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Partner Therapeutics Inc. on 25 March 2024 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 February 2025, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1, as amended.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for sargramostim, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for sargramostim, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

A waiver for sargramostim, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 4**

This decision is addressed to Partner Therapeutics Inc., 19 Muzzey Street, Lexington, MA 02421-5256, United States.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMADOC-1700519818-1804062  
Amsterdam, 28 February 2025

## Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA/PE/0000232765

### Scope of the application

#### Active substance(s):

Sargramostim

#### Invented name and authorisation status:

See Annex II

#### Condition(s):

Treatment of autoimmune pulmonary alveolar proteinosis

#### Pharmaceutical form(s):

Powder for nebuliser solution

#### Route(s) of administration:

Inhalation use

#### Name/corporate name of the PIP applicant:

Partner Therapeutics Inc.

### Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Partner Therapeutics Inc. submitted for agreement to the European Medicines Agency on 25 March 2024 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 29 April 2024.

Supplementary information was provided by the applicant on 21 November 2024. The applicant proposed modifications to the paediatric investigation plan.



## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

# 1. Waiver

## 1.1. Condition:

Treatment of pulmonary alveolar proteinosis

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- powder for nebuliser solution, inhalation use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

# 2. Paediatric investigation plan

## 2.1. Condition:

Treatment of pulmonary alveolar proteinosis

### 2.1.1. Indication(s) targeted by the PIP

Treatment of autoimmune pulmonary alveolar proteinosis

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

### 2.1.3. Pharmaceutical form(s)

Powder for nebuliser solution

### 2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	<b>Study 1</b> Open-label study to evaluate the safety and activity of sargramostim compared to placebo, following a whole lung lavage in paediatric patients from 6 years to less than 18 years of age with autoimmune pulmonary alveolar proteinosis in terms of estimation of treatment effects.
Modelling and simulation analyses	<b>Study 2</b> Modelling and simulation analyses to support of the paediatric development in the treatment of autoimmune pulmonary alveolar proteinosis in children from 6 years to less than 18 years of age with autoimmune pulmonary alveolar proteinosis.

Other studies	Not applicable
Extrapolation plan	Studies 1 and 2 are part of an extrapolation plan covering the paediatric population from 6 years to less than 18 years of age, as agreed by the PDCO.

### 3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2031
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

## **Annex II**

### **Information about the authorised medicinal product**

***Information provided by the applicant:***

**The product is not authorised anywhere in the European Community.**